Cognitive deficits in the euthymic phase of unipolar depression

Preiss, Marek; Kučerová, Hana Přikrylová; Lukavský, Jiřı́; Štěpánková, Hana; Sos, Petr; Kawaciukova, R.

doi:10.1016/j.psychres.2008.06.042

Cited by 109 publications

(66 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A valid Czech version of TMT B was used to assess executive functions, which is a test commonly used to evaluate cognitive flexibility. The results suggest impairment in cognitive flexibility in the group of patients Wilcoxon Matched Pairs Test, n=94; Z=2.132; p=0.033, showing that cognitive deficits persist even in the remission of the disorder [37].…”

Section: Executive Functions In Patients Recovering From Depressionmentioning

confidence: 87%

Executive Function Impairments in Patients with Depression

Alves¹,

Yamamoto²,

Arias-Carrión³

et al. 2014

CNSNDDT

View full text Add to dashboard Cite

Depression, the most prevalent psychiatric disorder, has a lifelong risk of 20% and is related to high rates of death among the patients. Thus, this study aims to conduct a systematic review of changes in executive functions of adult patients diagnosed with depression. We found 1381 articles; however, only 28 were selected and recovered. The inclusion criteria was the assessment of executive functions with at least one neuropsychological test, and articles that evaluated primarily adult individuals with depression, without comparison to other psychiatric disorders. Although most of the studies (25 out of 28 analyzed) have shown deficits in some executive subcomponents, these findings are not conclusive because they used different parameters of assessment. Moreover, many variables were not controlled, such as the different subtypes of the disorder, the high level of severity, comorbidity and the use of drugs. Most studies showed different deficits in executive functions in depressed patients, but further longitudinal studies are needed in order to confirm these findings.

show abstract

Section: Executive Functions In Patients Recovering From Depressionmentioning

confidence: 87%

Executive Function Impairments in Patients with Depression

Alves¹,

Yamamoto²,

Arias-Carrión³

et al. 2014

CNSNDDT

View full text Add to dashboard Cite

show abstract

“…[20][21][22] Critically, many of the same neural regions thought to mediate the cognitive (e.g., memory, executive functioning) and affective (e.g., emotion evaluation) processes necessary for social cognitive responding have been implicated in patients with bipolar disorder and MDD, showing altered metabolic functioning and/or structural abnormalities (for a recent review see Price and Drevets 23 ). Coupled with growing evidence of cognitive and affective processing impairments among patients with MDD and bipolar disorder, 20,[24][25][26][27][28] we expected our review to reveal that patients with mood disorders show alterations in neuronal functioning during social cognitive processing. Specifically, we expected that individuals with MDD and bipolar disorder would show lowered activation in prefrontal areas involved in emotion regulation and higher-order cognitive processes and increased activity in subcortical and limbic regions implicated in emotion appraisal and generation, indicating a lack of inhibition of higher-order cognitive centres on limbic and emotion-related structures.…”

Section: Introductionmentioning

confidence: 99%

Systematic review of the neural basis of social cognition in patients with mood disorders

Cusi

Nazarov

Holshausen

et al. 2012

J Psychiatry Neurosci

255

114

View full text Add to dashboard Cite

“…The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial reported remission rates of 37, 31, 14, and 13% after successive treatments in individuals with non-psychotic MDD using the 16-item Quick Inventory of Depressive Symptomatology (QIDS)-SelfReport (Rush et al, 2006). Even when depressive symptoms abate, cognitive problems may persist (Preiss et al, 2009;Reppermund et al, 2009), compromising an individual's coping ability and likelihood of successfully returning to work (Reppermund et al, 2009).…”

Section: Introductionmentioning

confidence: 99%

Lisdexamfetamine Dimesylate Augmentation in Adults With Persistent Executive Dysfunction After Partial or Full Remission of Major Depressive Disorder

Madhoo

Keefe

Roth

et al. 2013

Neuropsychopharmacol

View full text Add to dashboard Cite

Evaluate lisdexamfetamine dimesylate (LDX) augmentation of antidepressant monotherapy for executive dysfunction in partially or fully remitted major depressive disorder (MDD). This randomized, placebo-controlled study (NCT00985725) enrolled 143 adults (18-55 years) with mild MDD (Montgomery-Å sberg Depression Rating Scale (MADRS) score p18) and executive dysfunction (Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A) Self-Report Global Executive Composite (GEC) T score X60) on stable antidepressant monotherapy for X8 weeks. After 2 weeks of screening, participants were randomized to 9 weeks of double-blind LDX (20-70 mg/day) or placebo augmentation, followed by 2 weeks of single-blind placebo. The primary end point was change from baseline to week 9/end of study (EOS) in BRIEF-A Self-Report GEC T score; secondary assessments included the BRIEF-A Informant Report, MADRS, and treatment-emergent adverse events (TEAEs). Of 143 randomized participants, 119 completed double-blind treatment (placebo, n ¼ 59; LDX, n ¼ 60). Mean±standard deviation (SD) BRIEF-A GEC T scores decreased from baseline (placebo, 74.2±8.88; LDX, 76.8±9.66) to week 9/EOS (placebo, 61.4±14.61; LDX, 55.2±16.15); the LS mean (95% CI) treatment difference significantly favored LDX ( À 8.0 ( À 12.7, À 3.3); P ¼ 0.0009). The LS mean (95% CI) treatment difference for MADRS total score also significantly favored LDX ( À 1.9 ( À 3.7, 0.0); P ¼ 0.0465). TEAE rates were 73.6% with placebo and 78.9% with LDX; serious TEAE rates were 4.2 and 2.8%. In this trial, LDX augmentation significantly improved executive dysfunction and depressive symptoms in participants with mild MDD. The safety profile of LDX was consistent with prior studies in adults with attention-deficit/hyperactivity disorder.

show abstract

Cognitive deficits in the euthymic phase of unipolar depression

Cited by 109 publications

References 33 publications

Executive Function Impairments in Patients with Depression

Executive Function Impairments in Patients with Depression

Systematic review of the neural basis of social cognition in patients with mood disorders

Lisdexamfetamine Dimesylate Augmentation in Adults With Persistent Executive Dysfunction After Partial or Full Remission of Major Depressive Disorder

Contact Info

Product

Resources

About